Consistently, co-treatment with the mutant BRAF inhibitor PLX4720 inhibited reactivation of ERK and sensitized mutant BRAF colon cancer cells to AUY922-induced apoptosis (Figure 4D and 4E). Here, BRAF is linked to malignant colon neoplasm.